Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020
January 19, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
January 05, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
December 09, 2020 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences to Present at the 13th Annual LD Micro Main Event Virtual Conference
December 08, 2020 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020
November 16, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Announces Real-World Clinical Data for ILUVIEN® to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference
November 12, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Announces Third Quarter 2020 Financial Results
October 28, 2020 16:05 ET
|
Alimera Sciences, Inc.
Third Quarter Highlights: Consolidated Net Revenue of $12.5 Million Up 25% vs. Second Quarter 2020U.S. Net Revenue of $7.0 Million Up 106% vs. Second Quarter 2020Consolidated Net Revenue Down 3% vs....
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update
October 22, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a leader in the commercialization and development of prescription ophthalmology...
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress
September 23, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical to Commercialize Iluvien® in Austria and the Czech Republic
September 15, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...